<DOC>
	<DOCNO>NCT02113241</DOCNO>
	<brief_summary>The Metabolic Syndrome high prevalence disease worldwide . About quarter adult population suffers disease . Dapagliflozin inhibitor sodium-glucose co-transporter SGLT2 kidney novel treatment diabetes type 2 . Some study indicate SGLT2 inhibitor benefit blood pressure , triglyceride level help raise level high density lipoprotein cholesterol ( c-HDL ) . The aim study evaluate effect dapagliflozin metabolic syndrome , insulin sensitivity insulin secretion . The investigator hypothesis administration dapagliflozin modify metabolic syndrome , insulin sensitivity insulin secretion .</brief_summary>
	<brief_title>Effect Dapagliflozin Administration Metabolic Syndrome , Insulin Sensitivity , Insulin Secretion</brief_title>
	<detailed_description>A randomized , double-blind , placebo-controlled clinical trial go carry 24 patient diagnosis metabolic syndrome accordance International Diabetes Federation ( IDF ) . Waist circumference , glucose , insulin level , lipid profile , creatinine acid uric go load 75 g dextrose load . 12 patient receive Forxiga ( dapagliflozin ) , 10 mg , one per day breakfast 3 month . The remain 12 patient receive placebo dose . There calculated Area Under Curve glucose insulin , total insulin secretion ( insulinogenic index ) , first-phase insulin secretion ( Stumvoll index ) insulin sensitivity ( Matsuda index ) . This protocol 's already approve local ethic committee write informed consent 's go obtained volunteer . Results present mean standard deviation . Intra inter group differences go test use Wilcoxon signed-rank Mann-Whitney U-test respectively ; p≤0.05 's go consider significant .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients sexes Age 30 60 year Metabolic Syndrome accord IDF criterion Waist circumference Man ≥90 cm Woman ≥80 cm And two follow criterion High density lipoprotein Man ≤40 mg/dL Woman ≤50 mg/dL Fasting glucose ≥100 mg/dL Triglycerides ≥150 mg/dL Blood pressure ≥130/85 mmHg Informed consent sign Women confirm suspected pregnancy Women lactation and/or puerperium Hypersensibility SGLT2 inhibitor Physical impossibility take pill Known uncontrolled renal , hepatic , heart thyroid diseased Previous treatment metabolic syndrome component Body Mass Index ≥39.9 kg/m2 Fasting glucose ≥126 mg/dL Triglycerides ≥500 mg/dL Total cholesterol ≥240 mg/dL Low density lipoprotein ( cLDL ) ≥190 mg/dL Blood Pressure ≥140/90 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>metabolic syndrome</keyword>
	<keyword>forxiga</keyword>
	<keyword>dapagliflozin</keyword>
	<keyword>insulin secretion</keyword>
	<keyword>insulin sensitivity</keyword>
</DOC>